Poloxamer 188 - Phrixus Pharmaceuticals

Drug Profile

Poloxamer 188 - Phrixus Pharmaceuticals

Alternative Names: Carmeseal; Carmeseal-HF; Carmeseal-MD; P-188; P-188 NF

Latest Information Update: 18 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Phrixus Pharmaceuticals
  • Developer Ethicor Pharma; Phrixus Pharmaceuticals; University of Michigan
  • Class Anti-inflammatories; Antithrombotics; Cytoprotectives; Polyethylene glycols; Surfactants
  • Mechanism of Action Blood cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Duchenne muscular dystrophy
  • Preclinical Heart failure

Most Recent Events

  • 14 Sep 2017 Poloxamer 188 is still undergoing preclinical development for Heart failure in USA
  • 14 Sep 2017 Phrixus Pharmaceuticals and Cincinnati Children’s Hospital plan a phase II trial for Duchenne muscular dystrophy (In children, In adolescents, In adults) in USA (SC)
  • 07 Sep 2016 The US FDA approves IND application filed for Duchenne muscular dystrophy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top